Dendreon Corp. Reaches New 12-Month Low at $2.55 (DNDN)
Dendreon Corp. (NASDAQ:DNDN)’s share price reached a new 52-week low during trading hours on Tuesday, AnalystRatingsNetwork reports. The company traded as low as $2.55 and last traded at $2.56, with a volume of 3,250,676 shares traded. The stock had previously closed at $2.73.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Dendreon Corp. in a research note to investors on Monday. They now have a $3.00 price target on the stock. Separately, analysts at Maxim Group upgraded shares of Dendreon Corp. from a “sell” rating to a “hold” rating in a research note to investors on Wednesday, September 18th. They noted that the move was a valuation call. Finally, analysts at Needham & Company reiterated a “positive” rating on shares of Dendreon Corp. in a research note to investors on Tuesday, September 17th. Nine research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $5.00.
Dendreon Corp. has a 52 week low of $2.69 and a 52 week high of $7.22. The stock’s 50-day moving average is $2.97 and its 200-day moving average is $3.96. The company’s market cap is $398.5 million.
Dendreon Corp. (NASDAQ:DNDN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.42) by $0.03. The company had revenue of $73.30 million for the quarter, compared to the consensus estimate of $75.61 million. During the same quarter in the prior year, the company posted ($0.61) earnings per share. The company’s quarterly revenue was down 8.3% on a year-over-year basis. Analysts expect that Dendreon Corp. will post $-1.72 EPS for the current fiscal year.
Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.